Citations

Clear

18 citation(s) found for "Roberts, Jason A".

Management of Congenital Long-QT Syndrome: Commentary From the Experts
Kaufman, Elizabeth S. , Eckhardt, Lee L. , Ackerman, Michael J. , Aziz, Peter F. , Behr, Elijah R. , Cerrone, Marina , Chung, Mina K. , Cutler, Michael J. , Etheridge, Susan P. , Krahn, Andrew D. , Lubitz, Steven A. , Priori, Silvia G. , Roberts, Jason D. , Roden, Dan M. , Schulze‐Bahr, Eric , Shoemaker, M. Benjamin , Sy, Raymond W. , Towbin, Jeffrey A. , Wilde, Arthur A.M. , Zaręba, Wojciech , Behr, Elijah Raphael , Eckhardt, Lee L , Krahn, Andrew D , Lubitz, Steven A , Cerrone, Marina , Zareba, Wojciech , Priori, Silvia , Pérez, Marco , Roden, Dan M. , Schwartz, Peter J. , Shimizu, Wataru , Viskin, Sami

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 9, 2021 | Volume: 14 | Issue: 7 | Pages: No page available

10.1161/circep.120.009726 | PMID 34238011 Get It

While published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia
Ng, Kevin, Titus, Erron W. , Lieve, Krystien V.V. , Roston, Thomas M. , Mazzanti, Andrea , Deiter, Fred , Ingles, Jodie , Till, Jan , Robyns, Tomas , Connors, Sean P., Pang, B. , Bos, J. Martijn , Duffett, Stephen A. , Maltret, Alice , Green, Martin S. , Rutberg, Julie, Balaji, Seshadri , Cadrin‐Tourigny, Julia , Orland, Kate M. , Knight, Linda M., Brateng, Caitlin, Wu, Jeremy , Tang, Anthony , Skanes, Allan C. , Manlucu, Jaimie , January, Craig T., Collins, Kathryn K. , Maginot, Kathleen R., Fischbach, Peter , Etheridge, Susan P. , Eckhardt, Lee L. , Hamilton, Robert M. , Ackerman, Michael J. , Rosés‐Noguer, Ferran , Semsarian, Christopher , Jura, Natalia , Priori, Silvia G. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Deo, Rahul C. , Roberts, Jason D. , Eckhardt, Lee L , Bos, Johan M , Robyns, Tomas , Sanatani, Shubhayan , Hamilton, Robert , Rosés-Noguer, Ferran , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Ingles, Jodie , Priori, Silvia , Lieve, Krystien V , Denjoy, Isabelle , Connors, Sean P., Steinberg, Christian , Abrams, Dominic J. , Scheinman, Melvin M , Werf, Christian van der , Knight, Linda M., Healey, Jeff S. , Krahn, Andrew D. , Leenhardt, Antoine , Gollob, Michael H.

Mayo Clinic

Circulation | July 22, 2020 | Volume: 142 | Issue: 10 | Pages: 932-947

10.1161/circulationaha.120.045723 | PMID 32693635 Get It

Background: Genetic variants in calsequestrin-2 ( CASQ2 ) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2 -CPVT was sought through an international multicenter collaboration. Methods: Genotype-phenotype segregation in CASQ2 -CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. Results: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6–11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3–8.0; P =0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6–269.1; P <0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. Conclusions: This international multicenter study of CASQ2 -CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.
Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Lieve, Krystien V.V. , Dusi, Veronica , Werf, Christian van der , Bos, J. Martijn , Lane, Conor M. , Stokke, Mathis K. , Roston, Thomas M. , Djupsjöbacka, Aurora, Bundgaard, Henning , Rosés‐Noguer, Ferran , Semsarian, Christopher , Robyns, Tomas , Hofman, Nynke , Tanck, Michael W.T. , Berg, Maarten P. van den , Kammeraad, Janneke A.E. , Clur, Sally-Ann B., Sacher, Frédéric , Till, Jan , Skinner, Jonathan R. , Tfelt‐Hansen, Jacob , Horie, Minoru , Swan, Heikki, Roberts, Jason D. , Sanatani, Shubhayan , Haugaa, Kristina H. , Ackerman, Michael J. , Horie, Minoru , Bos, Johan M , Tanck, Michael , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Haugaa, Kristina , Sanatani, Shubhayan , van der Werf, Christian , Rosés-Noguer, Ferran , Bundgaard, Henning , Lieve, Krystien V , Dusi, Veronica , Wada, Yuko , Denjoy, Isabelle , Krahn, Andrew D. , Clur, Sally‐Ann B. , Probst, Vincent , Leenhardt, Antoine , Schwartz, Peter J. , Semsarian, Christopher

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 16, 2020 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/circep.119.007471 | PMID 32063070 Get It

Background: Risk stratification in catecholaminergic polymorphic ventricular tachycardia remains ill defined. Heart rate recovery (HRR) immediately after exercise is regulated by autonomic reflexes, particularly vagal tone, and may be associated with symptoms and ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Our objective was to evaluate whether HRR after maximal exercise on the exercise stress test (EST) is associated with symptoms and ventricular arrhythmias. Methods: In this retrospective observational study, we included patients ≤65 years of age with an EST without antiarrhythmic drugs who attained at least 80% of their age- and sex-predicted maximal HR. HRR in the recovery phase was calculated as the difference in heart rate (HR) at maximal exercise and at 1 minute in the recovery phase (ΔHRR1′). Results: We included 187 patients (median age, 36 years; 68 [36%] symptomatic before diagnosis). Pre-EST HR and maximal HR were equal among symptomatic and asymptomatic patients. Patients who were symptomatic before diagnosis had a greater ΔHRR1′ after maximal exercise (43 [interquartile range, 25–58] versus 25 [interquartile range, 19–34] beats/min; P <0.001). Corrected for age, sex, and relatedness, patients in the upper tertile for ΔHRR1′ had an odds ratio of 3.4 (95% CI, 1.6–7.4) of being symptomatic before diagnosis ( P <0.001). In addition, ΔHRR1′ was higher in patients with complex ventricular arrhythmias at EST off antiarrhythmic drugs (33 [interquartile range, 22–48] versus 27 [interquartile range, 20–36] beats/min; P =0.01). After diagnosis, patients with a ΔHRR1′ in the upper tertile of its distribution had significantly more arrhythmic events as compared with patients in the other tertiles ( P =0.045). Conclusions: Catecholaminergic polymorphic ventricular tachycardia patients with a larger HRR following exercise are more likely to be symptomatic and have complex ventricular arrhythmias during the first EST off antiarrhythmic drug.
An International Multicenter Evaluation of Type 5 Long QT Syndrome
Roberts, Jason D. , Asaki, S. Yukiko , Mazzanti, Andrea , Bos, J. Martijn , Tuleta, Izabela , Muir, Alison , Crotti, Lia , Kutyifa, Valentina , Shoemaker, M. Benjamin , Johnsrude, Christopher L. , Aiba, Takeshi , Marcondes, Luciana, Baban, Anwar , Udupa, Sharmila, Dechert, Brynn E. , Fischbach, Peter , Knight, Linda M., Kukavica, Deni , Stallmeyer, Birgit, Giudicessi, John R. , Spazzolini, Carla , Cadrin‐Tourigny, Julia , Simpson, Christopher S. , Roston, Thomas M. , Hajjaji, Imane El , Yousif, Maisoon D. , Gula, Lorne J. , Leong‐Sit, Peter , Chavali, Nikhil, Landstrom, Andrew P. , Marcus, Gregory M. , Dittmann, Sven , Wilde, Arthur A.M. , Behr, Elijah R. , Tfelt‐Hansen, Jacob , Kaski, Juan Pablo , Gow, Robert M., Aziz, Peter F. , Abrams, Dominic J. , Skinner, Jonathan R. , Kaufman, Elizabeth S. , Roden, Dan M. , Zaręba, Wojciech , Schulze‐Bahr, Eric , Etheridge, Susan P. , Priori, Silvia G. , Ackerman, Michael J. , Crotti, Lia , Behr, Elijah Raphael , Landstrom, Andrew P , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , Abrams, Dominic J , Baban, Anwar , Kaski, Juan P , Johnsrude, Christopher , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Zareba, Wojciech , Spazzolini, Carla , Priori, Silvia , Marcus, Gregory M , Krahn, Andrew D. , Aiba, Takeshi , Knight, Linda M., Vittinghoff, Eric , Shimamoto, Keiko , Tadros, Rafik , Duff, Henry J. , Wijeyeratne, Yanushi D. , Scheinman, Melvin M , Pérez, Marco , Drago, Fabrizio , Gollob, Michael H. , Shimizu, Wataru , Roden, Dan M. , Schwartz, Peter J.

Mayo Clinic

Circulation | January 16, 2020 | Volume: 141 | Issue: 6 | Pages: 429-439

10.1161/circulationaha.119.043114 | PMID 31941373 Get It

Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P <0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6–52.2]; P =0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3–10.8], P =0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.
Evidence Regarding Medication Overuse Headache in Children and Adolescents: Protocol for a Systematic Review
VanderPluym, Juliana H. , Gautreaux, Jessica , Burch, Rebecca , Whitaker, Evans , Roberts, Jason , Turner, Dana P. , Gelfand, Amy A. , Roberts, Jason , Gelfand, Amy A , VanderPluym, Juliana

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 8, 2020 | Volume: 60 | Issue: 1 | Pages: 171-177

10.1111/head.13726 | PMID 31913513 Get It

Objectives This proposed systematic review will identify the existing evidence on medication‐overuse headache in children and adolescents. Background A number of medications have been shown to be effective for acute treatment of migraine in children and adolescents. However, patients may find they need to use their acute medications more frequently when migraine frequency is high. This has led to concern about their potential to develop medication‐overuse headache. Methods We will search PubMed, Embase, Web of Science, PsycINFO, and Cochrane databases from their inception to present time. We will also search conference proceedings of the last 4 scientific meetings of relevant societies and scan the reference lists of studies identified through the search. Study designs will include case series, cross‐sectional, cohort, case‐control, and interventional studies. Participants will include children and adolescents under 18 years of age with primary headache disorders. We aim to determine whether frequency of acute medication use is associated with headache frequency in children and adolescents. Outcomes of interest include: (1) headache frequency; (2) change in headache frequency, with time and in relationship to use of acute medications; and (3) headache‐related disability. We will also review data addressing treatment/management of medication overuse or medication‐overuse headache in children and adolescents. Relevant comparators will be withdrawal vs reduction of acute medication, initiation of preventive therapy vs no initiation with or without withdrawal of acute medication, and initiation of preventive therapy early vs late. Outcomes of interest include (1) days of acute medication use; (2) headache frequency; (3) change in headache frequency; and (4) headache‐related disability. After screening for inclusion, 2 team members will independently review and extract relevant data, and any discrepancies will be resolved through discussion and arbitration. We will assess risk of bias using appropriate tools (Cochrane Risk of Bias for randomized controlled trials (RCT) and Newcastle‐Ottawa Score for observational studies). Data will be summarized descriptively in text and tables. Results This systematic review will provide an overview of the available evidence on medication‐overuse headache in children and adolescents. Conclusions Findings from this review will aid clinicians by clarifying for them the current state of the evidence base, and will inform design of future research on this topic.
Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site
Mellor, Greg , Panwar, Pankaj, Lee, Andrea K, Hathaway, Julie , Bartels, Kirsten , Balaji, Seshadri , Roberts, Jason D. , Simpson, Chris S., Boczek, Nicole J. , Tester, David J. , Radbill, Andrew E. , Mok, Ngai‐Shing, Hamilton, Robert M. , Kaufman, Elizabeth S. , Eugenio, Paul, January, Craig T., McDaniel, George, Leather, Richard, Falik, Shelley, Behr, Elijah R. , Wilde, Arthur A.M. , Sanatani, Shubhayan , Ackerman, Michael J. , Petegem, Filip Van , Laksman, Zachary , Behr, Elijah Raphael , Sanatani, Shubhayan , Hamilton, Robert , Steinberg, Christian , Christian, Susan , Weiss, Raul , Erickson, Christopher, Krahn, Andrew D.

Mayo Clinic

EP Europace | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1725-1732

10.1093/europace/euz215 | PMID 31408100 Get It

Abstract Aims Pathogenic gain-of-function variants in CACAN1C cause type-8 long QT syndrome (LQT8). We sought to describe the electrocardiographic features in LQT8 and utilize molecular modelling to gain mechanistic insights into its genetic culprits. Methods and results Rare variants in CACNA1C were identified from genetic testing laboratories. Treating physicians provided clinical information. Variant pathogenicity was independently assessed according to recent guidelines. Pathogenic (P) and likely pathogenic (LP) variants were mapped onto a 3D modelled structure of the Cav1.2 protein. Nine P/LP variants, identified in 23 patients from 19 families with non-syndromic LQTS were identified. Six variants, found in 79% of families, clustered to a 4-residue section in the cytosolic II–III loop region which forms a region capable of binding STAC SH3 domains. Therefore, variants may affect binding of SH3-domain containing proteins. Arrhythmic events occurred in similar proportions of patients with II–III loop variants and with other P/LP variants (53% vs. 48%, P = 0.41) despite shorter QTc intervals (477 ± 31 ms vs. 515 ± 37 ms, P = 0.03). A history of sudden death was reported only in families with II–III loop variants (60% vs. 0%, P = 0.03). The predominant T-wave morphology was a late peaking T wave with a steep descending limb. Exercise testing demonstrated QTc prolongation on standing and at 4 min recovery after exercise. Conclusion The majority of P/LP variants in patients with CACNA1C-mediated LQT8 cluster in an SH3-binding domain of the cytosolic II–III loop. This represents a ‘mutation hotspot’ in LQT8. A late-peaking T wave with a steep descending limb and QT prolongation on exercise are commonly seen.
@HeadacheJournal Tweets On
Robbins, Matthew S. , Shokrian, Neda, Roberts, Jason , Schwedt, Todd J. , Roberts, Jason , Robbins, Matthew S , Houle, Timothy T.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 30, 2019 | Volume: 59 | Issue: 6 | Pages: 828-833

10.1111/head.13539 | PMID 31144298 Get It

Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest
Werf, Christian van der , Lieve, Krystien V.V. , Bos, J. Martijn , Lane, Conor M. , Rosés‐Noguer, Ferran , Aiba, Takeshi , Wada, Yuko , Ingles, Jodie , Leren, Ida S. , Rudic, Boris , Maltret, Alice , Sacher, Frédéric , Skinner, Jonathan R. , Roston, Thomas M. , Tfelt‐Hansen, Jacob , Swan, Heikki, Robyns, Tomas , Ohno, Seiko , Roberts, Jason D. , Berg, Maarten P. van den , Kammeraad, Janneke A.E. , Blom, Nico A, Behr, Elijah R. , Borggrefe, Martin , Haugaa, Kristina H. , Semsarian, Christopher , Horie, Minoru , Till, Janice, Ackerman, Michael J. , Wilde, Arthur A.M. , Horie, Minoru , Behr, Elijah Raphael , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Haugaa, Kristina , Wada, Yuko , van der Werf, Christian , Rosés-Noguer, Ferran , Denjoy, Isabelle , Aiba, Takeshi , Schwartz, Peter J. , Krahn, Andrew D. , Ohno, Seiko , Probst, Vincent , Kannankeril, Prince J. , Blom, Nico A. , Shimizu, Wataru , Leenhardt, Antoine , Ingles, Jodie , Lieve, Krystien V

Mayo Clinic

European Heart Journal | April 26, 2019 | Volume: 40 | Issue: 35 | Pages: 2953-2961

10.1093/eurheartj/ehz309 | PMID 31145795 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), implantable cardioverter-defibrillator (ICD) shocks are sometimes ineffective and may even trigger fatal electrical storms. We assessed the efficacy and complications of ICDs placed in patients with CPVT who presented with a sentinel event of sudden cardiac arrest (SCA) while undiagnosed and therefore untreated. Methods and results We analysed 136 patients who presented with SCA and in whom CPVT was diagnosed subsequently, leading to the initiation of guideline-directed therapy, including β-blockers, flecainide, and/or left cardiac sympathetic denervation. An ICD was implanted in 79 patients (58.1%). The primary outcome of the study was sudden cardiac death (SCD). The secondary outcomes were composite outcomes of SCD, SCA, appropriate ICD shocks, and syncope. After a median follow-up of 4.8 years, SCD had occurred in three patients (3.8%) with an ICD and none of the patients without an ICD (P = 0.1). SCD, SCA, or appropriate ICD shocks occurred in 37 patients (46.8%) with an ICD and 9 patients (15.8%) without an ICD (P &lt; 0.0001). Inappropriate ICD shocks occurred in 19 patients (24.7%) and other device-related complications in 22 patients (28.9%). Conclusion In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.